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INTRODUCTION 
Hemostasis is a complex physiological process aimed at stop-
ping bleeding at the site of an injured blood vessel. The coagula-
tion cascade integrates both cellular and humoral reactions driv-
ing in opposite directions, one leading toward blood clot 
formation, the other to activation of the anticoagulation system 
that controls the extension of the clot in order to avoid damage to 
the organs.1 The pro-coagulant factors, through the activation of 
the tissue factor by factor VII and its interaction with the platelets 
membranes, lead to thrombin generation, conversion from fibrino-
gen to fibrin, and finally to blood clot formation.1 Meanwhile, 
thrombin itself, once complexed with its endothelial receptor 
thrombomodulin, activates plasma protein C. Activated protein C 
is a potent anticoagulant that, in combination with its plasma co-
factor protein S, down-regulates thrombin generation through the 
inhibition of the activated forms of factors VIII and V.1 The antico-
agulation effect is enhanced by plasma antithrombin, which, to-
gether with endothelial heparin-like substances, inhibits thrombin 
directly and indirectly through the inhibition of the activated 
forms of factors XI, IX, and X. Thrombin formation is also down-
regulated by the tissue factor pathway inhibitor (TFPI) that inhibits 
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the complex tissue factor-factor VII and activated factor X.1 Under 
normal conditions, meaning in normal individuals, there are high-
er levels of pro- and anticoagulant proteins than are needed for 
minimal hemostatic function. This functional ‘excess’ allows for a 
high degree of stability: the hemostatic balance tends to be main-
tained even under stress.
MODERN VIEW OF HEMOSTASIS: THE “CELL-
BASED MODEL”
In recent years, the “cell-based model” of hemostasis replaced 
the traditional “sequential model” and allowed a more accurate 
explanation of hemostatic process in vivo.2 Furthermore, in this 
model, it is possible to identify three different phases that simul-
taneously cooperate in vivo for adequate hemostasis: primary he-
mostasis, coagulation and fibrinolysis.
Primary hemostasis is defined as the interaction of platelets 
with exposed sub-endothelial surface at sites of vascular injury. 
Platelet adherence to sub-endothelium leads to the formation of 
the “platelet plug”. This process is mediated by adherence of 
plasma proteins [most important the glycoprotein Von Willebrand 
Factor] to specific receptors exposed on platelets membranes, re-
sulting in the adhesion of platelets to extracellular matrix proteins 
and subsequent aggregation to one another. A normal platelet 
number and function and normal plasma Von Willebrand Factor 
levels are all irreplaceable factors for a physiologic primary hemo-
stasis.
Coagulation (or Secondary hemostasis) is defined as the forma-
tion of insoluble cross-linked fibrin by activated coagulation fac-
tors. It is initiated simultaneously by the exposure of tissue factor 
(TF) on sub-endothelial layer. Formation of factor VIIa–TF complex 
initiate the coagulation cascade with activation of factor X and 
factor IX. Activated factor X and its cofactor (namely factor V) 
catalyze the activation of prothrombin to thrombin. At the same 
time, activated factor IX interacts with activated factor VIII, which 
is present on activated platelets membrane at site of vascular in-
jury, and this complex activates factor X with a strong amplifica-
tion of thrombin generation. Coagulation may therefore be de-
fined as the process that leads to thrombin generation through 
dynamic interaction of plasmatic coagulation proteins. Thrombin 
cleaves soluble fibrinogen causing the formation of insoluble fi-
brin clots, stabilized by activated factor XIII. In normal conditions 
thrombin generation is regulated by an anticoagulant system, in-
cluding antithrombin, protein C (activated by interaction between 
thrombin and its receptor thrombomodulin), protein S and the tis-
sue factor pathway inhibitor (TFPI). The balance between these 
opposite systems prevents pathological thrombin generation and 
excessive clot formation as well as uncontrolled bleeding.
Fibrin deposition activates also a fibrinolytic system, a further 
control for unwanted clot formation. Principal effector of fibrino-
lysis is plasmin, a protease derived from plasminogen, which is 
regulated by two activators, tissue plasminogen activator (tPA) 
and urokinase plasminogen activator (uPA). Plasmin cleaves fibrin 
in soluble degradation products. Anti-activators also regulate the 
system with anti-fibrinolytic activity, including specific inhibitors 
of tPA (PAI-1), plasmin inhibitors (e.g. alpha-1 plasmin inhibitor) 
and thrombin activatable fibrinolysis inhibitor (TAFI). The balance 
between pro- and anti-fibrinolytic factors is necessary to prevent 
uncontrolled plasmin generation and hyper- or hypo-fibrinolysis.3
ABNORMALITIES OF COAGULATION IN 
CHRONIC LIVER DISEASE
The liver is fundamental in the architecture of hemostasis not 
only because it synthetizes the majority of the pro- and anticoag-
ulants factors but also for the role played in their regulation, e. g. 
in clearing these factors from circulation through its reticulo-en-
dothelial system.
Liver disease profoundly affects coagulation. With the exception 
of Von Willebrand factor, which is secreted by endothelial cells, 
and calcium, it produces all factors involved in the coagulation 
process. Their production is impaired in case of hepatic insuffi-
ciency: this impairment is reflected by an increase in prothrombin 
time, which is the expression of the activity of factors I, II, V, VII 
and X.  Thus, individuals with advanced liver disease were previ-
ously considered as having a hypocoagulant and prohemorrhagic 
condition, exacerbated by a reduction in platelets count (due to 
portal hypertension).4 As a consequence, patients with liver cir-
rhosis were supposed to be protected against thrombosis. How-
ever, this belief is not correct: as patients with cirrhosis also have 
a reduction in anticoagulant proteins, to include antithrombin III, 
protein S, or C, and an increase of procoagulant factors (such as 
factor VIII or von Willebrand factor) their coagulative situation is 
characterized by a new balance of pro- and anticoagulation fac-
tors, defined as “rebalanced hemostasis”, with an inclination to-
ward bleeding or thrombotic events depending on the clinical set-
tings. The hemostatic balance is much harder to maintain when 
the levels of the pro- and anticoagulant factors are reduced by 
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hepatic insufficiency, but still there may not be a tendency to 
hemorrhage or thrombosis. However, in the occurrence of stress-
ful conditions, like infections, encephalopathy or bleeding, the 
fragile coagulative balance may be disrupted. 
Fibrinolytic system is also conditioned by hepatic function, as 
plasminogen, antiplasmin (alpha-2 plasmin inhibitor), plasmin in-
hibitor and TAFI are synthetized in the liver. Furthermore, in liver 
disease plasma levels of both tPA and its inhibitor PAI-1 (due to 
endothelial activation and reduced hepatic clearance) are in-
creased.5
Finally, chronic liver disease is usually characterized by a reduc-
tion of platelet count and alteration in platelet function. Thrombo-
cytopenia is the result of increased splenic and hepatic sequestra-
tion and destruction due to portal hypertension, as well as to 
reduced hepatic synthesis of thrombopoietin, a hormone that reg-
ulate proliferation and differentiation of megakaryocytes and 
platelet formation. Thrombocytopathy results from dysfunction of 
platelets due to alteration of proteins involved in platelet aggre-
gation process, including defective thromboxane A-2 synthesis by 
activated platelets or altered glycoprotein 1b, a platelet’s surface 
membrane protein.
In summary, the decreased hepatic synthetic function and the 
hemodynamic alterations due to portal hypertension exert a pro-
found influence on the hemostatic balance, accounting for the 
presence of altered coagulative parameters in patients with 
chronic liver disease. Routine blood tests (like International Nor-
malized Ratio [INR] or Partial Thromboplastin Time [PTT]) do not 
accurately evaluate the coagulative performance in these patients. 
When more dynamic tests like thromboelastography are used, the 
apparently deranged hemostasis is much less affected and is not 
associated with relevant complications even in invasive proce-
dures.6 
THROMBOTIC COMPLICATIONS IN CIRRHOSIS
As we had shown in the previous paragraph, recent evidences 
indicate that patients with liver disease are not more likely to de-
velop a hemorrhagic complication rather than a thrombotic one. 
Concepts like “auto-anticoagulation” or “natural protection of 
cirrhotic patients against thrombotic events” are outdated. In-
creased occurrence instead of venous thromboembolism (VTE) or 
venous thrombotic events (Portal Vein Thrombosis, PVT) has been 
recently reported.
Venous thromboembolism (VTE)
Several studies indicate the incidence of non-portal VTE in pa-
tients with chronic liver disease in a range between 0.5% and 
6.3%.7-9 Two retrospective studies by Northup et al.7 and Garcia-
Fuster et al.8, showed that the risk of developing VTE increases in 
patients with low serum albumin, but is independent from elevat-
ed INR or low platelet count. Serum albumin is a marker of liver 
synthetic function, and hence, indirectly, of the imbalance of se-
rum levels of anticoagulant factors as antithrombin III, protein C 
and protein S: this explains the increased risk of VTE in these pa-
tients. A retrospective study by Dabbagh et al.9 confirmed that an 
elevated INR (even >2.2) does not protect patients with chronic 
liver disease against the risk of VTE. Other studies showed that 
not only patients with cirrhosis are not naturally auto-anticoagu-
lated, but also they seem to have an increased relative risk of ve-
nous thromboembolism (both deep vein thrombosis and pulmo-
nary embolism) compared with controls.9-11 Wu et al.12 assessed the 
incidence of VTE in patients with compensated or decompensated 
cirrhosis and a random sample of control patients. Interestingly, re-
sults indicate that patients younger than 45 years have an in-
creased risk of VTE independently from being compensated or de-
compensated. After 45 years of age, patients with compensated 
cirrhosis had a lower risk of VTE, while those with decompensated 
disease had a similar risk compared with controls. These results 
may be explained with age-related factors not correlated with liver 
disease; in younger patients, who normally have low baseline risk 
of VTE, presence of cirrhosis imply an increased risk of VTE com-
pared with non cirrhotic patients, whereas in older patients extra-
hepatic factors seem to outweigh liver-related risk factors.
Portal vein thrombosis 
Portal vein thrombosis (PVT), the obstruction of portal vein 
and/or tributaries, is a relatively frequent event in cirrhotic pa-
tients; its incidence varying from 7.4% to 17.9% in different 
studies (Table 1).13-15 The development of PVT in cirrhosis is di-
rectly proportional to disease severity, being more frequent in 
individuals with decompensated cirrhosis. Although severe 
portal hypertension together with a reduction in portal blood 
flow speed facilitates the development of splanchnic venous 
thrombosis in patients with cirrhosis, the derangement of he-
mostatic balance in ALT plays also an important role especially 
in stressful clinical conditions. Beside decompensation, other 
situations are known risk factors for PVT in patients with cir-
16 http://www.e-cmh.org
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rhosis, to include endoscopic treatment of varices, abdominal 
surgery, injury to the portal venous system, and paradoxically 
also low platelets count, as well as bacterial infections. All 
these events are able to trigger the intrinsic pathway of coagu-
lation leading to blood clot formation. 
The pathogenesis of PVT includes both “systemic factors”, 
like those mentioned previously (coagulation abnormalities or 
presence of antiphospholipid antibodies16), and “local factors”, 
as peri-portal lymphangitis and fibrosis that lead to alteration 
of liver cytoarchitecture with consequent flow reduction and 
endothelial activation.17-19 Clinical presentation of PVT varies 
from asymptomatic to a medical emergency, depending on the 
extension and the rapidity of thrombus formation: “acute PVT” 
may be characterized by intestinal congestion and ischemia to 
peritonitis, shock and death.20 “Chronic PVT” may be asymp-
tomatic, but when discovered, the presence of varices and as-
cites should be investigated. Ultrasonography and Doppler ul-
trasound are usually first-line imaging method for the diagnosis 
of PVT, with a sensitivity and specificity variable from 66% to 
100%.21 Computed Tomography and Magnetic Resonance Im-
aging are however better for determining presence and extent 
of thrombosis, with a sensitivity and specificity near 100%.22-24 
ANTICOAGULATION IN CIRRHOSIS
Treatment of established PVT
Management of PVT in patients with cirrhosis is not reported 
in any guideline. There are no definitive consensus publications 
for prevention, treatment and monitoring of PVT in these pa-
tients. Anticoagulation is usually the first-line therapy, allowing 
a good chance of complete recanalization, a reduced incidence 
of portal hypertension complications and a decreased rate of 
thrombosis progression.24 Several studies are available indicat-
ing that anticoagulation, either through low molecular weight 
heparins (LMWH) or vitamin K antagonists’ administration, is 
both safe and effective in treating PVT (Table 2).12,24-36 Accord-
ing to the published data, following anticoagulation the rate of 
portal vein repermeation ranges from 40 to >90%, as com-
pared to 0% of the untreated controls. Severe side effects are 
practically absent, very few occurring with vitamin K antago-
nists. Importantly, increased hemorrhagic events are not re-
ported, and chronic administration of LMWH does not affect 
the outcome of gastro-intestinal bleeding following varices 
rupture: in a retrospective multicentric trial published in 2015, 
anticoagulation treatment for PVT or cardiovascular disorders 
did not increase neither the rate of treatment failure following 
varices rupture nor the 6 months mortality rate.37 Initiation of 
anticoagulation as early as possible is recommended, because 
early initiation of anticoagulation is the only factor significantly 
associated with repermeation. Anticoagulation should be initi-
ated with subcutaneous LMWH, which is as effective as intra-
venous heparin, does not require laboratory monitoring, has a 
more predictable dose response relationship, and has a lower 
risk of adverse events (i.e., heparin-induced thrombocytope-
nia). Anticoagulation is to be maintained for at least a 6 month 
duration, as repermeation beyond 4–6 months is unlikely; un-
fortunately, the recurrence of thrombosis after complete reper-
meation occurs in more than 35% of patients after stopping 
anticoagulation. Lifelong anticoagulation should be decided on 
an individualized case-to-case basis. 
It is advisable, before starting anticoagulation, to evaluate 
the presence of varices, and, in case of large varices or previ-
ous history of gastro-intestinal bleeding, start prophylaxis, ei-
ther with beta-blockers or endoscopic band ligation. Transjug-
ular Intrahepatic Porto-systemic Shunt (TIPS) results a valid 
alternative when anticoagulation fails, with a reported com-
plete recanalization of portal venous system in 57% of patients 
with cirrhosis, and a decrease in thrombosis in 30% of pa-
tients, but with the limitation that it could be considered only 
in experienced centers.38
Prophylaxis of PVT 
Since portal thrombosis is to be avoided, efforts should be 
Table 1. Prevalence of PVT in cirrhosis in different clinical settings
Type of PVT %
Overt
Screening for HCC                                     0.6
In-Hospital                                                  7.0
Necropsy 8.0-40
Before LTx or PSS                              15.0-25
Unrecognized
Small mural thrombus                             64
Large veins (intimal fibrosis)                   25
Small veins (intimal fibrosis)                   36
PVT, portal vein thrombosis; HCC, hepatocellular carcinoma; LTx, liver 
transplantation; PSS, portosystemic shunt.
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made also to prevent its development in individuals with cir-
rhosis. However, the use of anticoagulation in subjects with 
end-stage liver disease raised in the past some concerns about 
its safety, because heparin or vitamin K antagonists may tip 
the unsteady hemostatic balance of patients with cirrhosis to-
ward bleeding. These concerns were probably excessive. 
In 2012 we published a controlled trial where individuals 
with advanced cirrhosis were randomly assigned to receive or 
not enoxaparin 4,000 U subcutaneously daily: after 96 weeks, 
no PVT was seen in the treated group while 36% of the sub-
jects in the control group had signs of portal thrombosis. 
Moreover, no relevant side effects or hemorrhagic events were 
reported in the treated group, which showed also a lower inci-
dence of hepatic decompensation and an improved overall sur-
vival as compared to the untreated group. Prevention of PVT 
may not be the only event responsible for all these beneficial 
effects: heparin treatment itself could be of advantage in pre-
venting the progression of liver disease. A possible mechanism 
is that anticoagulation improves intestinal microcirculation, 
which in turn reduces bacterial translocation and thus the risk 
of bacterial infections. 
So far, this is the only published study on prophylaxis. How-
ever, two other multicenter randomized controlled study were 
started: one is Childbenox (NCT02271295) and the other is 
Cirroxaban (NCT02643212). While Childbenox protocol is very 
similar to our protocol and therefore it will allow, once com-
pleted, a meta-analysis of the raw data, Cirroxaban uses the 
new oral anticoagulant Rivaroxaban. Both are expected to pro-
vide data on the risks and benefits of proposing anticoagula-
tion in order to prevent PVT; most importantly, they will be 
able to confirm or not the beneficial effect on decompensation 
and survival shown in our study.  
Safety of anticoagulation
Treatment with LMWH was safe and effective, and not relat-
ed with an increased occurrence of bleeding. A recent retro-
spective analysis evaluating overall gastrointestinal bleeding in 
cirrhotic patients treated with anticoagulants ruled out antico-
agulation as an independent risk factor for bleeding or death.36 
A confirmation to these results was found in a retrospective 
cohort of patients with liver cirrhosis undergoing elective En-
doscopic Band Ligation (EBL). Among 26,742 upper endosco-
pies performed during the study period, 542 were prophylactic 
EBLs performed on 245 (200 primary and 45 secondary pro-
phylaxis) patients with liver cirrhosis. 197 EBL sessions were 
performed on 76 cases (4.81±0.92 bands per session) who 
were on LMWH while 345 EBL sessions were performed in 169 
controls (4.80±1.03). Clinical and endoscopic features were 
similar between the groups at the time of the first EBL. Overall 
5 patients bled (2%), 3 cases (3.9%) and 2 controls (1.2%, log 
rank 0.161), thus further confirming that anticoagulation with 
LMWH does not increase the risk of post-procedural bleeding 
patients with liver cirrhosis undergoing prophylactic EBL.39
CONCLUSIONS AND FUTURE DIRECTIONS
Patients with liver cirrhosis have a more complex coagulation 
state than previously believed. They display a global hemostat-
ic alteration, involving both pro- and anticoagulant factors. 
However, compensated patients have a substantially normal 
coagulative performance (“rebalanced hemostasis”).3,4,40 De-
compensated patients present bleeding as a complication of 
portal hypertension, mostly from gastro-intestinal varices. 
However, the contribution of deranged hemostasis as a precip-
itating factor is poorly documented and the impact of coagula-
tion in this setting is not well established. What it is clear is 
that standard coagulation tests are inappropriate to define the 
complex coagulation state of patients with liver cirrhosis and 
dynamic tests like thromboelastography should be used in-
stead.6
The occurrence of thrombotic events, which are major con-
tributors of variceal bleeding, has been previously underesti-
mated. A better knowledge of this complication and of its 
mechanisms has changed the paradigm and the clinical man-
agement of the patients (i.e. the use of anticoagulants). Anti-
coagulation should be started as soon as the thrombotic com-
plication is diagnosed and continued for at least 6 months. 
There are no strict indications on whether it should be contin-
ued indefinitely.  
The major challenge, however, is to define whether prophy-
lactic anticoagulation should be instituted in patients with cir-
rhosis and when. Data from a prospective randomized study14 
showed that anticoagulation not only prevented the occurrence 
of portal vein thrombosis but, most importantly, decreased the 
occurrence of decompensation and improved survival. Two 
other studies with anticoagulants and with the same endpoints 
are currently ongoing (Childbenox, NCT02271295, and Cirroxa-
ban, NCT02643212). Their results are eagerly awaited. 
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